@article{9a2a75cbdef64b43a5d931477ea849ab,
title = "Every reason to discontinue lithium",
abstract = "Lithium as a gold standard therapy for bipolar disorder is well known to have a number of medical comorbidities that impact renal, parathyroid, and thyroid function. Despite these medical comorbidities, there remains a group of lithium-responsive lithium-treated patients who have maintained mood stability for decades. The risk/benefit ratio of end organ toxicity/mood stability must be evaluated in each individual case.",
keywords = "Efficacy, Lithium, Toxicity",
author = "Salgado, {Manuel E.Fuentes} and Bruce Sutor and Albright, {Robert C.} and Frye, {Mark A.}",
note = "Funding Information: Dr. Frye declares as potential competing interests grant support (AssureRx, Janssen Research & Development, Mayo Foundation, Myriad, National Institute of Alcohol Abuse and Alcoholism, National Institute of Mental Health, Pfizer), consultant (Janssen Research & Development, LLC, Mitsubishi Tanabe Pharma Corporation, Myriad, Sunovion, Supernus Pharmaceuticals, Teva Pharmaceuticals), and CME/Travel Support (CME Outfitters Inc.). The remaining authors declare that they have no competing interests. Publisher Copyright: {\textcopyright} 2014, Salgado et al.; licensee Springer.",
year = "2014",
doi = "10.1186/s40345-014-0012-y",
language = "English (US)",
volume = "2",
pages = "1--3",
journal = "International Journal of Bipolar Disorders",
issn = "2194-7511",
publisher = "Springer Open",
number = "1",
}